Bamlanivimab (INN, codenamed LY-CoV555) is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020 and 950,000 doses have been bought by the US government as of December 2020.
The drug is an IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. The aim is to block viral attachment and entry into human cells, thus neutralizing the virus, and help preventing and treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Bamlanivimab is a new expensive monoclonal antibody drug given via infusion over the course of 1 hour. Patients are then monitored for another hour for possible side effects or adverse reactions. It's been given EUA by the FDA to treat the virus.
A life saved is a family saved.
Abhijit Naskar
B.C. CEO says life-saving COVID-19 treatment is 'sitting on the shelf'
https://youtu.be/7RE3qtyy68U
The drug is an IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. The aim is to block viral attachment and entry into human cells, thus neutralizing the virus, and help preventing and treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Bamlanivimab is a new expensive monoclonal antibody drug given via infusion over the course of 1 hour. Patients are then monitored for another hour for possible side effects or adverse reactions. It's been given EUA by the FDA to treat the virus.
https://en.wikipedia.org/wiki/Bamlanivimab
https://en.wikipedia.org/wiki/AbCellera
https://www.fda.gov/media/143603/download
https://www.omniaradiationbalancer.com/?p=HJYwF3eYw
https://www.goodreads.com/quotes/tag/medical-treatment
https://www.blood.ca/en/stories/link-between-blood-type-and-covid-19-severity#:~:text=A%20recent%20study%20coauthored%20by,blood%20groups%20B%20or%20O.
https://www.tctmd.com/news/german-covid-19-autopsy-data-show-thromboembolism-heavy-lungs
https://www.archyde.com/international-criminal-court-accepts-israeli-governments-nuremberg-code-violation-complaint/amp/
https://www.ibtimes.sg/who-eric-bannec-negligent-doctor-made-dr-susan-moore-feel-like-addict-before-her-death-54430A life saved is a family saved.
Abhijit Naskar
B.C. CEO says life-saving COVID-19 treatment is 'sitting on the shelf'
https://youtu.be/7RE3qtyy68U